治疗耐药鲍曼不动杆菌的抗菌新药  

Novel antimicrobial agents for the treatment of drug resistant Acinetobacter baumannii

作　　者：蔺飞 凌保东[2] Lin Fei;Ling Bao-dong(Department of Pharmacy,Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College,Chengdu 610500;Sichuan Province College Key Laboratory of Structure-Specific Small Molecule Drugs,School of Pharmacy,Chengdu Medical College,Chengdu 610500)

机构地区：[1]成都医学院第一附属医院药学部,成都610500 [2]成都医学院结构特异性小分子药物研究四川省高校重点实验室,成都610500

出　　处：《中国抗生素杂志》2023年第1期41-48,共8页Chinese Journal of Antibiotics

基　　金：国家自然科学基金委项目(No.81373454)。

摘　　要：耐药鲍曼不动杆菌导致的院内感染暴发给临床治疗带来极大挑战,因此迫切需要开发新型抗菌药物。本文就近年来研究开发或批准上市治疗耐药鲍曼不动杆菌的抗菌新药,包括β-内酰胺酶抑制剂、头孢菌素类、氨基糖苷类、喹诺酮类及新型抗菌药物进行综述。The treatment of nosocomial infection that caused by drug-resistant Acinetobacter baumannii has great challenges, and thus it is urgent to develop new antimicrobial agents. This review focuses on the new antibacterial drugs which were developed or approved in recent years for killing the drug-resistant A. baumannii,including β-lactamase inhibitors, cephalosporins, aminoglycosides, quinolones, and others.

关 键 词：碳青霉烯类耐药鲍曼不动杆菌 新型抗菌药物 

分 类 号：R978.1[医药卫生—药品]